Φορτώνει......
Safety of Same-Day Pegfilgrastim Administration in Metastatic Castration-Resistant Prostate Cancer Treated With Cabazitaxel With Or Without Carboplatin
INTRODUCTION: Although myeloid growth factors are commonly used to treat metastatic castration-resistant prostate cancer (mCRPC), the optimal timing of administration has not been well studied. We assessed the effects of same-day pegfilgrastim, a neutrophil stimulator, after cabazitaxel treatment wi...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Clin Genitourin Cancer |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
2016
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5446270/ https://ncbi.nlm.nih.gov/pubmed/28038931 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2016.12.003 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|